AxoGen, Inc. $AXGN Shares Bought by Acadian Asset Management LLC

Acadian Asset Management LLC lifted its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 53.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,726 shares of the medical equipment provider’s stock after buying an additional 120,914 shares during the period. Acadian Asset Management LLC owned approximately 0.76% of AxoGen worth $3,772,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AXGN. AlphaQuest LLC increased its stake in shares of AxoGen by 882.2% in the 2nd quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock worth $68,000 after acquiring an additional 5,637 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in AxoGen during the first quarter worth about $146,000. KLP Kapitalforvaltning AS purchased a new position in AxoGen during the first quarter worth about $150,000. Versor Investments LP acquired a new position in AxoGen in the 1st quarter valued at about $192,000. Finally, Jones Financial Companies Lllp boosted its holdings in AxoGen by 104,810.0% in the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 10,481 shares during the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AxoGen

In other AxoGen news, Director William P. Mr. Burke sold 40,235 shares of AxoGen stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $20.55, for a total value of $826,829.25. Following the transaction, the director directly owned 100 shares in the company, valued at approximately $2,055. The trade was a 99.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 133,600 shares of company stock worth $2,839,945. Company insiders own 2.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AXGN. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating on shares of AxoGen in a research report on Wednesday, October 29th. HC Wainwright boosted their price target on shares of AxoGen from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Raymond James Financial lifted their target price on shares of AxoGen from $20.00 to $27.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.86.

AxoGen Stock Down 2.0%

AXGN stock opened at $23.55 on Friday. The stock has a market cap of $1.09 billion, a P/E ratio of -471.00 and a beta of 1.09. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. AxoGen, Inc. has a twelve month low of $9.22 and a twelve month high of $24.92. The company’s 50 day moving average is $18.71 and its two-hundred day moving average is $14.78.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The firm had revenue of $60.08 million during the quarter, compared to analysts’ expectations of $56.90 million. AxoGen had a negative return on equity of 1.96% and a negative net margin of 0.98%. AxoGen has set its FY 2025 guidance at EPS. Research analysts expect that AxoGen, Inc. will post -0.29 earnings per share for the current fiscal year.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.